Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

La eficacia y seguridad de Elritercept en participantes adultos con síndromes mielodisplásicos (MDS) de riesgo muy bajo, bajo o intermedio con anemia (RENEW)

5 de noviembre de 2026 actualizado por: Takeda

Un estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de Elritercept (KER-050) para el tratamiento de la anemia dependiente de transfusiones en participantes adultos con riesgo muy bajo, bajo o intermedio Síndromes mielodisplásicos (MDS) (RENOVAR)

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a Phase 3, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of elritercept (TAK-226, KER-050) versus placebo. Elritercept (TAK-226, KER-050) is an investigational medicinal product being developed for the treatment of anemia in adult participants with a diagnosis of lower-risk myelodysplastic neoplasms/syndromes. After all required Screening Period assessments are completed, and eligibility is confirmed, participants will be randomized and enter the Primary Phase of the Double-Blind Treatment Period. Participants will be randomly assigned in a 2:1 ratio to receive either elritercept (TAK-226, KER-050) or placebo subcutaneously (SC) every 4 weeks (Q4W). Participants will be stratified according to their ring sideroblasts (RS) status (RS-positive versus non-RS) and baseline transfusion burden (low-transfusion burden [LTB] versus high transfusion burden [HTB]). The Primary Phase of the Double-blind Treatment Period will last 24 weeks. The Secondary Phase of the Double-Blind Treatment Period will last an additional 24 weeks. During the Secondary Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment they received during the Primary Phase. Study visits will occur approximately every 2 weeks from Cycle 1 through Cycle 6 and every 4 weeks from Cycle 7 through the remainder of the Double-Blind Treatment Period. During the Extension Phase of the Double-Blind Treatment Period, all eligible participants will continue to receive the same double-blind treatment they received during the Primary and Secondary Phases. Participants will continue in the Extension Phase until they individually discontinue or until the study is unblinded. For participants to remain on double-blind treatment, they must meet the criteria outlined in the MDS disease assessment criteria every 24 weeks. Based on the outcome of the Week 24 MDS disease assessment, participants will either continue in the Extension Phase of the Double-blind Treatment Period or will be discontinued from treatment and proceed to End of Treatment and then into the Safety Follow-up Period. The Safety Follow-Up Period will extend from the last dose of study treatment through 8 weeks after the last dose of study treatment. Study visits should occur every 4 weeks within the Safety Follow-Up Period. Long-term follow-up will take place quarterly after a participant has completed the Safety Follow-Up Period. Long-term follow-up will continue for 5 years from the first dose of study treatment, or until a participant is deceased, is lost to follow-up, withdraws consent, or the study closes, whichever is earliest.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

225

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Takeda Contact
  • Número de teléfono: +1-877-825-3327
  • Correo electrónico: medinfoUS@takeda.com

Ubicaciones de estudio

      • Berlin, Alemania, 10715
        • Reclutamiento
        • Praxis am Volkspark Berlin
        • Investigador principal:
          • Jan-Piet Habbel
        • Contacto:
      • Berlin, Alemania, 12203
        • Reclutamiento
        • Charite Universitatsmedizin Berlin
        • Investigador principal:
          • Kathrin Rieger
        • Contacto:
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Alemania, 53127
        • Aún no reclutando
        • University Hospital Bronn
        • Investigador principal:
          • Karin Mayer
        • Contacto:
      • Düsseldorf, North Rhine-Westphalia, Alemania, 40479
        • Reclutamiento
        • Marien Hospital Duesseldorf GmbH, Clinic for Oncology, Hematology and Palliative Medicine
        • Contacto:
        • Investigador principal:
          • Aristoteles Giagounidis
    • Saxony
      • Leipzig, Saxony, Alemania, 04103
        • Reclutamiento
        • University Hospital Leipzig, Clinic and Policlinic for Internal Medicine I Haematology and Stem Cell Therapy, Medical Oncology, Haemostaseology
        • Investigador principal:
          • Dominic Brauer
        • Contacto:
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Alemania, 06120
        • Reclutamiento
        • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology
        • Contacto:
        • Investigador principal:
          • Haifa Al-Ali
      • Magdeburg, Saxony-Anhalt, Alemania, 39120
        • Aún no reclutando
        • University Clinic of Hematology, Oncology and Cell Therapy
        • Investigador principal:
          • Berisha Mirjeta
        • Contacto:
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2605
        • Aún no reclutando
        • The Canberra Hospital
        • Investigador principal:
          • Philip Choi
        • Contacto:
    • New South Wales
      • Sydney, New South Wales, Australia, 2145
        • Reclutamiento
        • Westmead Hospital
        • Contacto:
        • Investigador principal:
          • Lachlin Vaughan
    • Queensland
      • Douglas, Queensland, Australia, 4814
        • Reclutamiento
        • Townsville University Hospital
        • Investigador principal:
          • Joel Wight
        • Contacto:
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Reclutamiento
        • Royal Adelaide Hospital
        • Contacto:
        • Investigador principal:
          • Devendra Hiwase
      • Adelaide, South Australia, Australia, 5042
        • Reclutamiento
        • Flinders Medical Centre
        • Contacto:
        • Investigador principal:
          • Ashanka Beligaswatte
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Reclutamiento
        • Box Hill Hospital
        • Contacto:
        • Investigador principal:
          • Genevieve Douglas
      • Fitzroy, Victoria, Australia, 3065
        • Reclutamiento
        • St Vincent's Hospital (Melbourne) Ltd
        • Contacto:
        • Investigador principal:
          • ShuhYing Tan
      • Melbourne, Victoria, Australia, 3004
        • Aún no reclutando
        • Alfred Health
        • Investigador principal:
          • Shaun Fleming
        • Contacto:
      • Parkville, Victoria, Australia, 3000
        • Reclutamiento
        • Peter MacCallum Cancer Center
        • Contacto:
        • Investigador principal:
          • Lynette Chee
      • Rio de Janeiro, Brasil, 22775-001
      • São Paulo, Brasil, 01323-900
        • Reclutamiento
        • Portuguese Charity of Sao Paulo, Clinical Hematology / Oncology Center
        • Contacto:
          • Site Contact
          • Número de teléfono: +55 (11) 3505 6615
          • Correo electrónico: scheinbp@gmail.com
        • Investigador principal:
          • Phillip Scheinberg
      • São Paulo, Brasil, 01509-900
        • Reclutamiento
        • Hospital A.C.Camargo ("Antonio Prudente" Foundation)
        • Investigador principal:
          • Marina Nascimento
        • Contacto:
      • São Paulo, Brasil, 11075-900
        • Reclutamiento
        • Santa Casa of Mercy of Santos
        • Investigador principal:
          • Elaine Mancilha
        • Contacto:
    • Paraná
      • Curitiba, Paraná, Brasil, 81520-060
        • Reclutamiento
        • Hosptial Erasto Gaertner
        • Contacto:
        • Investigador principal:
          • Eduardo Munhoz
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90610-000
        • Reclutamiento
        • Pontifical University Of Rio Grande Do Sul (PUCRS) - St. Luke Hospital
        • Investigador principal:
          • Mariza Schaan
        • Contacto:
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • Reclutamiento
        • Porto Alegre Clinical Hospital (HCPA)
        • Investigador principal:
          • Laura Maria Fogliatto
        • Contacto:
      • Porto Alegre, Rio Grande do Sul, Brasil, 90110-270
        • Reclutamiento
        • Hospital Mae de Deus, Clinical Research Unit - Cancer Institute
        • Investigador principal:
          • Marcelo Capra
        • Contacto:
    • Santa Catarina
      • Joinville, Santa Catarina, Brasil, 89201-260
        • Reclutamiento
        • Instituto Joinvilense de Hematologia e Oncologia
        • Contacto:
        • Investigador principal:
          • Lacerda Marcelo
    • São Paulo
      • Jaú, São Paulo, Brasil, 17210-080
      • Santo André, São Paulo, Brasil, 09060-650
        • Reclutamiento
        • Cepho- Fmabc
        • Contacto:
        • Investigador principal:
          • Vitor Mauad
      • São José do Rio Preto, São Paulo, Brasil, 15090-000
        • Reclutamiento
        • Sao Jose do Rio Preto Regional Faculty of Medicine Foundation
        • Investigador principal:
          • Mariana Buka
        • Contacto:
      • Plovdiv, Bulgaria, 4002
        • Reclutamiento
        • Dr. Pencho Georgiev - Outpatient Center for Individual Practice for Specialized Medical Care in Internal Medicine and Clinical Hematology (EOOD)
        • Contacto:
        • Investigador principal:
          • Pencho Georgiev
      • Sofia, Bulgaria, 1431
        • Reclutamiento
        • University Multiprofile Hospital for Active Treatment "Sveti Ivan Rilski", Sofia, Clinic of Clinical Hematology
        • Investigador principal:
          • Atanas Radinoff
        • Contacto:
      • Sofia, Bulgaria, 1606
        • Reclutamiento
        • Multiprofile Hospital for Active Treatment - Sofia, part of Military Medical Academy, Clinic of Hematology
        • Contacto:
        • Investigador principal:
          • Viktoria Barbukova
      • Sofia, Bulgaria, 1797
        • Reclutamiento
        • Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Clinic of Hematology
        • Contacto:
        • Investigador principal:
          • Tanya Yankova
      • Varna, Bulgaria, 9010
        • Aún no reclutando
        • University Multiprofile Hospital for Active Treatment "Sveta Marina", Clinic of Clinical Hematology
        • Investigador principal:
          • Ilina Micheva
        • Contacto:
    • Alberta
      • Edmonton, Alberta, Canadá, T6G 2B7
        • Reclutamiento
        • University of Alberta Hospital
        • Contacto:
        • Investigador principal:
          • Nancy Zhu
    • British Columbia
      • Vancouver, British Columbia, Canadá, V6Z 2A5
        • Reclutamiento
        • Providence Hematology - Vancouver
        • Contacto:
        • Investigador principal:
          • Heather Leitch
    • Nova Scotia
      • Halifax, Nova Scotia, Canadá, B3H 1V7
        • Reclutamiento
        • Nova Scotia Health Authority, Centre for Clinical Research
        • Contacto:
        • Investigador principal:
          • Amy Trottier
    • Ontario
      • London, Ontario, Canadá, N6A 4L6
        • Reclutamiento
        • London Health Sciences Centre
        • Investigador principal:
          • Lalit Saini
        • Contacto:
      • Toronto, Ontario, Canadá, M5G 2M9
        • Reclutamiento
        • Princess Margaret Cancer Centre
        • Contacto:
          • Site Contact
          • Número de teléfono: +1 (416) 946 4501
          • Correo electrónico: Karen.Yee@uhn.ca
        • Investigador principal:
          • Karen Yee
      • Toronto, Ontario, Canadá, M4N 3M5
        • Reclutamiento
        • Sunnybrook Research Institute, Odette Cancer Center
        • Investigador principal:
          • Rena Buckstein
        • Contacto:
      • Brno, Chequia, 625 00
        • Reclutamiento
        • University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology
        • Investigador principal:
          • Jiri Mayer
        • Contacto:
      • Hradec Králové, Chequia, 500 05
        • Reclutamiento
        • University Hospital Hradec Kralove, 4th Internal Clinic of Hematology
        • Contacto:
        • Investigador principal:
          • Petra Belohlavkova
      • Ostrava, Chequia, 70852
        • Reclutamiento
        • Charles University General Hospital
        • Investigador principal:
          • Anna Jonasova
        • Contacto:
      • Ostrava, Chequia, 70852
        • Reclutamiento
        • University Hospital Ostrava and Faculty of Medicine, University of Ostrava
        • Contacto:
        • Investigador principal:
          • Zdenek Koristek
      • Prague, Chequia, 100 00
        • Reclutamiento
        • University Hospital Kralovske Vinohrady, Clinic of Internal Hematology
        • Contacto:
          • Site Contact
          • Número de teléfono: + (420) 267 162 887
          • Correo electrónico: olga.cerna@fnkv.cz
        • Investigador principal:
          • Olga Cerna
      • Prague, Chequia, 12800
        • Reclutamiento
        • Institute of Hematology and Blood Transfusion, Division of Training and Development
        • Investigador principal:
          • Marketa Stastna-Markova
        • Contacto:
      • Santiago, Chile, 7500653
        • Reclutamiento
        • SAGA Clinical Research Center SpA
        • Investigador principal:
          • Ada Hernandez
        • Contacto:
      • Santiago, Chile, 7580206
        • Reclutamiento
        • Clinic Inmunocel
        • Contacto:
        • Investigador principal:
          • Jose Vinuela
      • Santiago, Chile, 8320000
        • Reclutamiento
        • Center for Clinical Studies and Medical Research (CECIM)
        • Investigador principal:
          • Alexander Arellano
        • Contacto:
    • Biobio
      • Concepción, Biobio, Chile, 4070356
        • Reclutamiento
        • Dr. Guillermo Grant Benavente - Concepcion Regional Hospital
        • Investigador principal:
          • Monica Romero
        • Contacto:
    • Coquimbo Region
      • La Serena, Coquimbo Region, Chile, 1720430
        • Reclutamiento
        • IC La Serena Research
        • Investigador principal:
          • Cleiden Villegas
        • Contacto:
      • Daegu, Corea del Sur, 41944
        • Reclutamiento
        • Kyungpook National University Hospital
        • Contacto:
          • Site Contact
          • Número de teléfono: +82 (53) 200 5570
          • Correo electrónico: jhmoon74@knuh.kr
        • Investigador principal:
          • Joon ho Moon
      • Seoul, Corea del Sur, 05505
        • Reclutamiento
        • Asan Medical Center
        • Investigador principal:
          • Je-Hwan Lee
        • Contacto:
          • Site Contact
          • Número de teléfono: +82 (2) 3010 3218
          • Correo electrónico: jhlee3@amc.seoul.kr
      • Seoul, Corea del Sur, 03080
        • Reclutamiento
        • Seoul National University Hospital
        • Investigador principal:
          • Junshik Hong
        • Contacto:
      • Seoul, Corea del Sur, 06351
        • Reclutamiento
        • Samsung Medical Center
        • Investigador principal:
          • Jun Ho Jang
        • Contacto:
      • Seoul, Corea del Sur, 04401
        • Reclutamiento
        • Soon Chun Hyang University Hospital Seoul
        • Investigador principal:
          • Seug Yun Yoon
        • Contacto:
      • Seoul, Corea del Sur, 06591
        • Reclutamiento
        • The Catholic University of Korea, Seoul St. Mary's Hospital
        • Investigador principal:
          • Yoo Jin Kim
        • Contacto:
    • Castille and León
      • Salamanca, Castille and León, España, 37007
        • Reclutamiento
        • University Clinical Hospital of Salamanca, Department of Hematology
        • Investigador principal:
          • Maria Diez Campelo
        • Contacto:
    • Catalonia
      • Barcelona, Catalonia, España, 08035
        • Reclutamiento
        • University Hospital Vall d'Hebron, Department of Hematology
        • Investigador principal:
          • David Valcarcel Ferreiras
        • Contacto:
          • Site Contact
          • Número de teléfono: +34 (932) 746 100
          • Correo electrónico: dvalcarcel@vhio.net
    • Girona
      • L'Hospitalet de Llobregat, Girona, España, 08908
        • Reclutamiento
        • Catalan Institute of Oncology, Hospital Duran i Reynals, Department of Clinical Hematology
        • Investigador principal:
          • Montserrat Arnan Sangerman
        • Contacto:
    • Madrid
      • Madrid, Madrid, España, 28034
        • Reclutamiento
        • University Hospital Ramon y Cajal
        • Investigador principal:
          • Kyra Velazquez Kennedy
        • Contacto:
      • Madrid, Madrid, España, 28040
        • Reclutamiento
        • University Hospital Foundation Jimenez Diaz
        • Investigador principal:
          • Teresa Arquero Portero
        • Contacto:
          • Site Contact
          • Número de teléfono: 34-915-50-4800
          • Correo electrónico: tarquero@fjd.es
    • Valencia
      • Valencia, Valencia, España, 46026
        • Reclutamiento
        • University and Polytechnic Hospital La Fe
        • Investigador principal:
          • Elvira Mora Castera
        • Contacto:
          • Site Contact
          • Número de teléfono: 34-961-24-4000
          • Correo electrónico: mora_elv@gva.es
    • California
      • Duarte, California, Estados Unidos, 91010
        • Reclutamiento
        • City of Hope
        • Investigador principal:
          • Andrew Artz
        • Contacto:
          • Site Contact
          • Número de teléfono: 626-218-2404
          • Correo electrónico: aartz@coh.org
      • Glendale, California, Estados Unidos, 91206
        • Reclutamiento
        • Los Angeles Cancer Network
        • Investigador principal:
          • Eric Lee
        • Contacto:
      • La Jolla, California, Estados Unidos, 92037
        • Reclutamiento
        • UC San Diego Moores Cancer Center
        • Investigador principal:
          • Amanda Kagan
        • Contacto:
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06511
        • Reclutamiento
        • Smilow Cancer Hospital at Yale-New Haven
        • Investigador principal:
          • Amer Zeidan
        • Contacto:
    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • Reclutamiento
        • University of Miami Hospital and Clinics
        • Contacto:
        • Investigador principal:
          • Mikkael Sekeres
      • Tampa, Florida, Estados Unidos, 33612
        • Reclutamiento
        • Moffitt Cancer Center
        • Contacto:
        • Investigador principal:
          • Rami Komrokji
    • Illinois
      • Peoria, Illinois, Estados Unidos, 61645
        • Reclutamiento
        • ILCC. Illinois Cancer Centers
        • Contacto:
        • Investigador principal:
          • Paul Fishkin
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40207
        • Reclutamiento
        • Norton Cancer Institute
        • Investigador principal:
          • Don Stevens
        • Contacto:
    • Louisiana
      • Monroe, Louisiana, Estados Unidos, 71201
        • Reclutamiento
        • Ghattas Oncology
        • Investigador principal:
          • Tharwat Ghattas
        • Contacto:
    • Maryland
      • Columbia, Maryland, Estados Unidos, 21044
        • Reclutamiento
        • Maryland Oncology Hematolofy
        • Investigador principal:
          • Mohit Narang
        • Contacto:
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64132
        • Reclutamiento
        • MidAmerica Cancer Care
        • Contacto:
        • Investigador principal:
          • Benjamin Fangman
    • Nevada
      • Henderson, Nevada, Estados Unidos, 89169
        • Reclutamiento
        • Comprehensive Cancer Centers of Nevada
        • Investigador principal:
          • Edwin Kingsley
        • Contacto:
    • New York
      • Westbury, New York, Estados Unidos, 11590
        • Reclutamiento
        • Clinical Research Alliance NY
        • Investigador principal:
          • Jonathan Goldberg
        • Contacto:
    • North Carolina
      • Winston-Salem, North Carolina, Estados Unidos, 27013
        • Reclutamiento
        • Novant Health-Cancer Institute
        • Investigador principal:
          • James Dugan
        • Contacto:
    • Ohio
      • Canton, Ohio, Estados Unidos, 44718
        • Reclutamiento
        • Gabrail Cancer Center Research
        • Investigador principal:
          • Nashat Gabrail
        • Contacto:
      • Cleveland, Ohio, Estados Unidos, 44195
        • Reclutamiento
        • Cleveland Clinic - Cleveland
        • Contacto:
          • Site Contact
          • Número de teléfono: 216-445-7942
          • Correo electrónico: jaina9@ccf.org
        • Investigador principal:
          • Akriti Jain
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37909
        • Reclutamiento
        • Tennessee Cancer Specialists
        • Contacto:
        • Investigador principal:
          • Tracy Dobbs
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • Vanderbilt University Medical Center
        • Investigador principal:
          • Ashwin Kishtagari
        • Contacto:
    • Texas
      • Denison, Texas, Estados Unidos, 75020
        • Reclutamiento
        • Texas Oncology Northeast Texas
        • Investigador principal:
          • Amir Faridi
        • Contacto:
      • Houston, Texas, Estados Unidos, 77090
        • Reclutamiento
        • LUMI Research
        • Investigador principal:
          • David Nguyen
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • U.T. MD Anderson Cancer Center, Division of Cancer Medicine
        • Investigador principal:
          • Guillermo Garcia-Manero
        • Contacto:
      • Red Oak, Texas, Estados Unidos, 75154
        • Reclutamiento
        • Epic Medical Research
        • Investigador principal:
          • Kirtan Koticha
        • Contacto:
      • The Woodlands, Texas, Estados Unidos, 77380
        • Reclutamiento
        • Texas Oncology Gulf Coast
        • Investigador principal:
          • Andrew Jackson
        • Contacto:
      • Webster, Texas, Estados Unidos, 77598-4085
        • Reclutamiento
        • Tranquil Research
        • Investigador principal:
          • John Knecht
        • Contacto:
    • Washington
      • Issaquah, Washington, Estados Unidos, 98029
        • Aún no reclutando
        • Epic Care Emeryville
        • Contacto:
        • Investigador principal:
          • Rajesh Behl
      • Nice, Francia, 06200
        • Reclutamiento
        • Archet 1 and 2 hospital
        • Investigador principal:
          • Thomas Cluzeau
        • Contacto:
      • Paris, Francia, 75010
        • Reclutamiento
        • Saint-Louis Hospital
        • Investigador principal:
          • Lionel Ades
        • Contacto:
          • Site Contact
          • Número de teléfono: +33 (1) 7120 7021
          • Correo electrónico: lionel.ades@aphp.fr
      • Poitiers, Francia, 86000
        • Reclutamiento
        • Poitiers University Hospital Center - Miletrie Site
        • Investigador principal:
          • Jose Miguel Torregrosa-Diaz
        • Contacto:
      • Toulouse, Francia, 31059
        • Reclutamiento
        • IUCT-Oncopole
        • Contacto:
        • Investigador principal:
          • Thibault Comont
      • Budapest, Hungría, H-1088
        • Reclutamiento
        • Semmelweis University, Department of Internal Medicine and Haematology, Division of Hematology
        • Investigador principal:
          • Zsolt Nagy
        • Contacto:
      • Debrecen, Hungría, 4032
        • Reclutamiento
        • University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology
        • Investigador principal:
          • Arpad Illes
        • Contacto:
      • Kaposvár, Hungría, H-7400
        • Reclutamiento
        • Mor Kaposi General Hospital, Department of Hematology
        • Contacto:
        • Investigador principal:
          • Miklos Egyed
      • Nyíregyháza, Hungría, 4400
        • Reclutamiento
        • Szabolcs-Szatmar-Bereg County Teaching Hospital, Department of Hematology
        • Investigador principal:
          • Laszlo Rejto
        • Contacto:
      • Székesfehérvár, Hungría, H-8000
        • Reclutamiento
        • Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine III, Hematology
        • Contacto:
        • Investigador principal:
          • Arpad Szomor
      • Delhi, India, 110085
        • Aún no reclutando
        • Rajiv Gandhi Cancer Institute & Research Centre
        • Contacto:
          • Site Contact
          • Número de teléfono: 9971500861
          • Correo electrónico: Bhurani@gmail.com
        • Investigador principal:
          • Dinesh Bhurani
      • Gūrgaon, India, 122018
        • Reclutamiento
        • Medanta the Medicity
        • Contacto:
        • Investigador principal:
          • Nitin Sood
    • Gujarat
      • Ahmedabad, Gujarat, India, 380009
        • Reclutamiento
        • Heamto Oncology Clinic Ahmedabad Pvt. Ltd.
        • Contacto:
        • Investigador principal:
          • Sandip Shah
      • Ahmedabad, Gujarat, India, 382428
        • Reclutamiento
        • Apollo Hospital International Ltd
        • Contacto:
        • Investigador principal:
          • Velu Nair
    • Kerala
      • Ernākulam, Kerala, India, 682041
        • Aún no reclutando
        • Amrita Institute of Medical Sciences
        • Contacto:
        • Investigador principal:
          • Neeraj Siddharthan
    • Maharashtra
      • Mumbai, Maharashtra, India, 400012
        • Aún no reclutando
        • Tata Memorial Centre
        • Contacto:
        • Investigador principal:
          • Alok Shetty
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110029
        • Reclutamiento
        • All India Institute of Medical Science
        • Contacto:
        • Investigador principal:
          • Tulika Seth
    • Punjab
      • Ludhiana, Punjab, India, 380006
        • Reclutamiento
        • Christian Medical College, Ludhianana
        • Contacto:
        • Investigador principal:
          • Joseph John
    • Tamil Nadu
      • Vellore, Tamil Nadu, India, 632004
        • Reclutamiento
        • Christian Medical College
        • Contacto:
        • Investigador principal:
          • Biju George
    • Uttar Pradesh
      • Ghaziabad, Uttar Pradesh, India, 201012
        • Aún no reclutando
        • Max Super Speciality Hospital Vaishali (A Unit Of Crosslay Remedies Ltd.)
        • Contacto:
        • Investigador principal:
          • Pradeep Kumar
    • West Bengal
      • Kolkata, West Bengal, India, 700014
        • Reclutamiento
        • NRS Medical College and Hospital
        • Contacto:
        • Investigador principal:
          • Tuphan Kanti Dolai
      • Kolkata, West Bengal, India, 700156
        • Reclutamiento
        • Tata Medical Center, Kolkata
        • Contacto:
        • Investigador principal:
          • Arijit Nag
      • Cork, Irlanda, T12 DC4A
        • Reclutamiento
        • Cork University Hospital
        • Investigador principal:
          • Vitaliy Mykytiv
        • Contacto:
      • Dublin, Irlanda, D07 R2WY
        • Reclutamiento
        • Mater Misericordiae University Hospital
        • Investigador principal:
          • Su Maung
        • Contacto:
          • Site Contact
          • Número de teléfono: 353-1-803-2000
          • Correo electrónico: SuMaung@mater.ie
      • Dublin, Irlanda, D24 NR0A
        • Reclutamiento
        • Tallaght University Hospital
        • Investigador principal:
          • Helen Enright
        • Contacto:
      • Dublin, Irlanda, D05 DK31
        • Reclutamiento
        • Beaumont Hospital
        • Investigador principal:
          • Philip Murphy
        • Contacto:
      • Dublin, Irlanda, DO4 T6F4
        • Reclutamiento
        • St Vincent's University Hospital (SVUH)
        • Investigador principal:
          • Claire Andrews
        • Contacto:
      • Limerick, Irlanda, V94 F858
        • Reclutamiento
        • University Hospital Limerick
        • Contacto:
        • Investigador principal:
          • Cian McEllistrim
      • Jerusalem, Israel, 9112001
        • Reclutamiento
        • Hadassah Medical Center, Department of Hematology
        • Contacto:
        • Investigador principal:
          • Revital Saban
      • Petah Tikva, Israel, 49100
        • Reclutamiento
        • Rabin Medical Center, Davidoff Cancer Center, Hemato-Oncology Institute
        • Investigador principal:
          • Ofir Wolach
        • Contacto:
          • Site Contact
          • Número de teléfono: +972 (3) 937 8116
          • Correo electrónico: owolach@gmail.com
      • Ramat Gan, Israel, 5266202
        • Reclutamiento
        • Chaim Sheba Medical Center, Department of Hematology, Myelodysplastic Syndromes Center
        • Investigador principal:
          • Drorit Merkel
        • Contacto:
      • Tel Aviv, Israel, 6423906
        • Reclutamiento
        • The Tel Aviv Sourasky Medical Center, Department of Hematology and Bone Marrow Transplantation, Leukemia Service
        • Investigador principal:
          • Yakir Moshe
        • Contacto:
      • Florence, Italia, 50134
        • Reclutamiento
        • Careggi University Hospital
        • Investigador principal:
          • Valeria Santini
        • Contacto:
      • Milan, Italia, 20122
        • Reclutamiento
        • Maggiore Polyclinic Hospital, Foundation IRCCS Ca' Granda
        • Investigador principal:
          • Bruno Fattizzo
        • Contacto:
      • Pavia, Italia, 27100
        • Reclutamiento
        • Polyclinic San Matteo, IRCCS, Department of Oncohematology, Operative Unit of Hematology
        • Contacto:
        • Investigador principal:
          • Luca Malcovati
      • Reggio Calabria, Italia, 89133
        • Reclutamiento
        • Granda Ospedale Metropolitano 'Bianchi-Melacrino-Morelli'
        • Contacto:
        • Investigador principal:
          • Caterina Alati
      • Rome, Italia, 00133
        • Reclutamiento
        • Foundation PTV - Polyclinic Tor Vergata
        • Investigador principal:
          • Maria Teresa Voso
        • Contacto:
      • Rozzano, Italia, 20089
        • Reclutamiento
        • Clinical Institute Humanitas, IRCCS
        • Investigador principal:
          • Matteo Giovanni Della Porta
        • Contacto:
      • Turin, Italia, 10060
        • Reclutamiento
        • Institute of Cancer Research and Treatment of Candiolo
        • Investigador principal:
          • Elena Crisa
        • Contacto:
    • AN
      • Ancona, AN, Italia, 60126
        • Reclutamiento
        • Aou Delle Marche
        • Investigador principal:
          • Antonella Poloni
        • Contacto:
    • Piedmont
      • Turin, Piedmont, Italia, 10128
        • Reclutamiento
        • AO Ordine Mauriziano
        • Investigador principal:
          • Daniela Cilloni
        • Contacto:
      • Kaunas, Lituania, LT-50161
        • Reclutamiento
        • Hospital of Lithuanian University of Health Sciences Kauno Klinikos
        • Contacto:
        • Investigador principal:
          • Milda Rudzianskiene
      • Vilnius, Lituania, LT-08406
        • Reclutamiento
        • Vilnius University Hospital Santaros Klinikos
        • Investigador principal:
          • Andrius Degulys
        • Contacto:
      • Bellavista, Perú, 07016
        • Aún no reclutando
        • Daniel Alcides Carrion National Hospital
        • Investigador principal:
          • Jose Chinen Pemberton
        • Contacto:
      • Lima, Perú, 15038
        • Aún no reclutando
        • National Institute of Neoplastic Diseases
        • Contacto:
        • Investigador principal:
          • Jule Vasquez
    • Jesus Maria
      • Lima, Jesus Maria, Perú, 15073
        • Aún no reclutando
        • Edgardo Rebagliati Martins National Hospital
        • Contacto:
        • Investigador principal:
          • Lourdes Aranda
    • La Molina
      • Lima, La Molina, Perú, 15023
        • Reclutamiento
        • Anglo American Clinic
        • Investigador principal:
          • Antonio Carrasco
        • Contacto:
    • San Isidro Lima
      • Lima, San Isidro Lima, Perú, 02002
        • Reclutamiento
        • IPOR: Peruvian Institute of Oncology & Radiotherapy
        • Investigador principal:
          • Maria Vera Vasquez
        • Contacto:
      • Katowice, Polonia, 40-519
        • Reclutamiento
        • Pratia Oncology Katowice
        • Investigador principal:
          • Sebastian Grosicki
        • Contacto:
      • Lodz, Polonia, 93-513
        • Reclutamiento
        • Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, General Hematology Unit
        • Investigador principal:
          • Tadeusz Robak
        • Contacto:
      • Olsztyn, Polonia, 10-228
        • Reclutamiento
        • Clinical Hospital Of The Ministry Of Internal Affairs And Administration With Warmia And Mazury Oncology Centre In Olsztyn, Clinical Department of Hematology and Internal Medicine with Bone Marrow Transplantation Center
        • Investigador principal:
          • Janusz Halka
        • Contacto:
    • Greater
      • Poznan, Greater, Polonia, 60-192
        • Reclutamiento
        • Pratia Poznan
        • Contacto:
        • Investigador principal:
          • Anna Hoppe
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polonia, 50-019
        • Reclutamiento
        • Pratia Onkologia Wroclaw
        • Contacto:
        • Investigador principal:
          • Justyna Rybka
      • Birmingham, Reino Unido, B15 2TH
        • Reclutamiento
        • Queen Elizabeth Hospital Birmingham
        • Investigador principal:
          • Vidhya Murthy
        • Contacto:
      • Cambridge, Reino Unido, CB2 0QQ
        • Reclutamiento
        • Addenbrooke's Hospital
        • Investigador principal:
          • Duncan Brian
        • Contacto:
      • Leeds, Reino Unido, LS9 7TF
        • Reclutamiento
        • St James's University Hospital
        • Contacto:
        • Investigador principal:
          • Catherine Cargo
      • London, Reino Unido, SE5 9RS
        • Reclutamiento
        • King's College Hospital
        • Investigador principal:
          • Austin Kulasekararaj
        • Contacto:
      • London, Reino Unido, W1G 6AD
        • Reclutamiento
        • Sarah Cannon Research Institute (SCRI)
        • Investigador principal:
          • Jennifer O'Sullivan (Dillon)
        • Contacto:
      • Manchester, Reino Unido, M20 4BX
        • Reclutamiento
        • The Christie NHS Foundation Trust
        • Investigador principal:
          • Daniel Wiseman
        • Contacto:
      • Nottingham, Reino Unido, NG5 1PB
        • Reclutamiento
        • Nottingham City Hospital
        • Investigador principal:
          • Jennifer Byrne
        • Contacto:
      • Oxford, Reino Unido, OX3 7LE
        • Reclutamiento
        • Churchill Hospital
        • Contacto:
        • Investigador principal:
          • Oni Chowdhury
    • Aberdeen City
      • Aberdeen, Aberdeen City, Reino Unido, AB25 2ZN
        • Reclutamiento
        • Aberdeen Royal Infirmary
        • Investigador principal:
          • Dominic Culligan
        • Contacto:
    • Denbighshire
      • Rhyl, Denbighshire, Reino Unido, LL18 5UJ
        • Reclutamiento
        • Glan Clwyd Hospital
        • Investigador principal:
          • Earnest Heartin
        • Contacto:
    • Leics
      • Leicester, Leics, Reino Unido, LE1 5WW
        • Reclutamiento
        • University Hospitals of Leicester
        • Investigador principal:
          • Matthew Lee
        • Contacto:
    • Lincolnshire
      • Lincoln, Lincolnshire, Reino Unido, LN2 5QY
        • Reclutamiento
        • Lincolnshire Community and Hospitals NHS group
        • Investigador principal:
          • Ciro Rinaldi
        • Contacto:
    • Tyne and Wear
      • High Heaton, Tyne and Wear, Reino Unido, NE7 7DN
        • Reclutamiento
        • The Newcastle Upon Tyne University Hospitals Foundation Trust
        • Contacto:
        • Investigador principal:
          • Michelle Lannon
      • Sunderland, Tyne and Wear, Reino Unido, SR4 7TP
        • Aún no reclutando
        • South Tyneside and Sunderland Foundation Trust
        • Investigador principal:
          • Scott Marshall
        • Contacto:
      • Cape Town, Sudáfrica, 7580
        • Reclutamiento
        • Haemalife
        • Contacto:
        • Investigador principal:
          • Michael Cass
      • Durban, Sudáfrica, 4091
        • Reclutamiento
        • Capital Haematology Hospital
        • Investigador principal:
          • Jaimendra Singh
        • Contacto:
      • Johannesburg, Sudáfrica, 2193
        • Reclutamiento
        • Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center
        • Contacto:
        • Investigador principal:
          • Johnny Mahlangu
      • Pretoria, Sudáfrica, 0181
        • Reclutamiento
        • Alberts Cellular Therapy
        • Investigador principal:
          • Andrew McDonald
        • Contacto:
      • Lund, Suecia, 221 85
        • Reclutamiento
        • Skane University Hospital - Lund, Department of Hematology and Vascular Disorders
        • Contacto:
        • Investigador principal:
          • Lars Nilsson
    • A-rebro County
      • Örebro, A-rebro County, Suecia, 70185
        • Aún no reclutando
        • A-rebro University Hospital, Hematology Department
        • Contacto:
        • Investigador principal:
          • Bengt Rasmussen
    • Stockholm County
      • Huddinge, Stockholm County, Suecia, 141 57
        • Reclutamiento
        • Karolinska University Hospital
        • Investigador principal:
          • Magnus Tobiasson
        • Contacto:
    • VG
      • Gothenburg, VG, Suecia, 41345
        • Aún no reclutando
        • Sahlgrenska University Hospital
        • Contacto:
        • Investigador principal:
          • Lena Von Bahr
      • Bern, Suiza, 3010
        • Aún no reclutando
        • Insel Gruppe AG, University Clinic for Hematology and Central Hematological Laboratory
        • Contacto:
        • Investigador principal:
          • Natalia Baran
      • Zurich, Suiza, 8091
        • Reclutamiento
        • Universitatsspital Zurich, Klinik fur Medizinische Onkologie und Hamatologie
        • Contacto:
        • Investigador principal:
          • Stefan Balabanov
    • Canton of Basel-City
      • Basel, Canton of Basel-City, Suiza, 4031
        • Aún no reclutando
        • University Hosptial Basel
        • Contacto:
        • Investigador principal:
          • Gregor Stehle
      • Bangkok, Tailandia, 10330
        • Reclutamiento
        • King Chulalongkorn Memorial Hospital
        • Contacto:
        • Investigador principal:
          • Noppacharn Uaprasert
      • Bangkok, Tailandia, 10400
        • Reclutamiento
        • Ramathibodi Hospital
        • Contacto:
        • Investigador principal:
          • Piyajaroenkij Thanakrit
      • Bangkok, Tailandia, 10400
        • Reclutamiento
        • Rajavithi Hospital
        • Contacto:
          • Site Contact
          • Número de teléfono: +66 (2) 206 2900
          • Correo electrónico: kunapa@gmail.com
        • Investigador principal:
          • Kunapa Iam-arunthai
      • Bangkok, Tailandia, 74210
        • Reclutamiento
        • Banphaeo General Hospital
        • Investigador principal:
          • Busakorn Sae-Aeng
        • Contacto:
      • Chiang Mai, Tailandia, 50200
        • Reclutamiento
        • Maharaj Nakorn Chiangmai Hospital
        • Contacto:
        • Investigador principal:
          • Thanawat Rattanathammethee
      • Taichung, Taiwán, 407219
        • Reclutamiento
        • Taichung Veterans General Hospital
        • Investigador principal:
          • Cheng-Hsien Lin
        • Contacto:
      • Tainan, Taiwán, 704302
        • Reclutamiento
        • National Cheng Kung University Hospital
        • Investigador principal:
          • Tsai-Yun Chen
        • Contacto:
      • Taipei, Taiwán, 100225
        • Reclutamiento
        • National Taiwan University Hospital
        • Investigador principal:
          • Wen-Chien Chou
        • Contacto:
          • Site Contact
          • Número de teléfono: 886-2-2312-3456
          • Correo electrónico: wchou@ntu.edu.tw
      • Taoyuan City, Taiwán, 333
        • Reclutamiento
        • Linkou Chang Gung Memorial Hospital
        • Investigador principal:
          • Ming-Chung Kuo
        • Contacto:
          • Site Contact
          • Número de teléfono: 886-3-328-1200
          • Correo electrónico: kmc12069@gmail.com
    • Changhua County
      • Changhua, Changhua County, Taiwán, 500209
        • Reclutamiento
        • Changhua Christian Hospital
        • Contacto:
          • Site Contact
          • Número de teléfono: 886-4-723-8595
          • Correo electrónico: 155627@cch.org.tw
        • Investigador principal:
          • Ruo-Han Tseng
      • Changhua, Changhua County, Taiwán, 50544
        • Reclutamiento
        • Chang Bing Show Chwan Memorial Hospital
        • Investigador principal:
          • Cheng-Shyong Chang
        • Contacto:
          • Site Contact
          • Número de teléfono: 886-4-781-3888
          • Correo electrónico: cs4816@gmail.com
      • Adana, Turquía (Türkiye), 01370
        • Reclutamiento
        • Adana City Hospital
        • Contacto:
        • Investigador principal:
          • Elif Suyani
      • Ankara, Turquía (Türkiye), 06170
        • Reclutamiento
        • Ankara Etlik City Hospital
        • Investigador principal:
          • Merih Kizil Cakar
        • Contacto:
      • Ankara, Turquía (Türkiye), 06600
        • Aún no reclutando
        • Ankara University Medical Faculty Cebeci Hospital
        • Investigador principal:
          • Selami Toprak
        • Contacto:
          • Site Contact
          • Número de teléfono: 90-312-595-6000
          • Correo electrónico: sktoprak@yahoo.com
      • Antalya, Turquía (Türkiye), 07100
        • Reclutamiento
        • Antalya Education and Training Hospital
        • Investigador principal:
          • Volkan Karakus
        • Contacto:
      • Mersin, Turquía (Türkiye), 33200
        • Reclutamiento
        • Mersin Medicalpark Hospital
        • Investigador principal:
          • Anil Tombak
        • Contacto:
      • Sakarya, Turquía (Türkiye), 54290
        • Reclutamiento
        • Sakarya University Medical Faculty Hospital
        • Investigador principal:
          • Cenk Sunu
        • Contacto:
      • Samsun, Turquía (Türkiye), 55139
        • Reclutamiento
        • Ondokuz Mayis University School of Medicine, Department of Hematology
        • Contacto:
          • Site Contact
          • Número de teléfono: +90 (505) 272 2289
          • Correo electrónico: engink@omu.edu.tr
        • Investigador principal:
          • Engin Kelkitli

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information and/or protected personal data in accordance with national and local study participant data protections and privacy regulations.

  • Male or female greater than or equal to (≥)18 years of age at the time of signing informed consent.

  • Diagnosis of MDS with or without RS (as determined in an evaluable bone marrow sample, read by an independent central reader to confirm diagnosis at Screening) according to the World Health Organization 2016 classification that meets the International Prognostic Scoring System-Revised (IPSS-R) classification of very low, low, or intermediate risk disease. In cases where a local bone marrow (BM) assessment establishing an MDS diagnosis was conducted within 12 weeks prior to informed consent form (ICF) signature, the associated local BM samples and/or reports may be permitted.

  • Transfusion dependence assessed in the 16 weeks immediately preceding randomization in two 8-week blocks, classified as either:

    a. LTB, defined as 4 to 7 RBC units per 16 weeks; or b. HTB, defined as ≥8 RBC units per 16 weeks; and c. For all participants: i. Only transfusion events for a pretransfusion hemoglobin (Hgb) lesser than (<)10 grams per deciliter (g/dL) are counted toward eligibility; ii. At least 1 transfusion event in each 8-week period and a minimum of 2 transfusion events separated by ≥7 days within the 16-week period immediately preceding randomization; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16-week period immediately preceding randomization.

  • Refractory or intolerant to prior erythropoiesis-stimulating agent (ESA) treatment (discontinued ≥4 weeks before randomization), or unlikely to respond to ESA treatment, defined as follows:

    a. Refractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (e.g., with granulocyte colony-stimulating factor [G-CSF]); ESA regimen must have been either: i. Recombinant human erythropoietin (EPO) ≥30,000 international units per week (IU/week) for ≥8 doses or equivalent; or ii. Darbepoetin alpha ≥500 micrograms (μg) every 3 weeks for ≥3 doses or ≥ 120 μg every week for ≥ 8 doses or equivalent.

    b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA-containing regimen, either as a single agent or combination (e.g., with G-CSF), at any time after introduction due to intolerance or an AE.

    c. Unlikely to respond to ESA treatment: low chance of response to ESA based on an endogenous serum EPO level greater than (>)200 units per liter (U/L).

  • Less than 5 percent (%) blasts in an evaluable bone marrow sample collected at Screening.

  • Eastern Cooperative Oncology Group performance status of 0 to 2.

  • Females of childbearing potential and sexually active males must agree to use highly effective methods of contraception.

  • In the opinion of the Investigator, the participant is able and willing to comply with the requirements of the protocol (e.g., all study procedures, return for follow-up visits).

Exclusion Criteria:

  • Del(5q) MDS, secondary MDS (MDS with a documented history of prior exposure to chemotherapy, radiotherapy, or other leukemogenic agents that is considered causally related to the development of MDS).

  • Anemia due to any other known cause (e.g., thalassemia, hemolytic anemia, bleeding events, or deficiency of iron, B12, and/or folate).

  • Receipt of RBC transfusion for any reason(s) other than underlying MDS within 16 weeks before randomization.

  • Clinically significant cardiovascular disease defined as:

    1. New York Heart Association heart disease class III or IV;
    2. Fridericia corrected QT (QTcF) interval >500 milliseconds during Screening;
    3. Presence of uncontrolled hypertension defined as mean systolic blood pressure ≥160 millimeters of mercury (mm Hg) or diastolic blood pressure ≥100 mm Hg during Screening; or
    4. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before Screening.
  • Known ejection fraction <35%, confirmed by a local echocardiogram performed during Screening, or a previously performed echocardiogram if collected within 6 months before Screening.

  • Child-Pugh class C hepatic impairment.

  • Stroke, deep vein thrombosis, or pulmonary embolism within 6 months before Screening.

  • Any known history of acute myeloid leukemia (AML).

  • Prior history of malignancies, other than MDS, unless participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for ≥ 2 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:

    1. Basal or squamous cell carcinoma of the skin;
    2. Carcinoma in situ of the cervix;
    3. Carcinoma in situ of the breast; and/or
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system).
    5. Early papillary thyroid cancer (stage I [T1-T2, N0, M0]).
  • History of solid organ or bone marrow transplantation.

  • Active infection requiring intravenous treatment (e.g., antibiotics, antifungals, or antivirals) within 28 days, or oral treatment within 14 days before randomization.

  • Active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV). Participants with a history of HIV infection may be enrolled if they are receiving antiretroviral therapy and have a documented CD4+ T cell count > 200 cells per microliter (cells/μL) at screening. Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.

  • Body mass index ≥ 40 kilograms per meter square (kg/m^2).

  • Major surgery within 28 days before randomization.

  • History of allergy/anaphylaxis to investigational medicinal product (IMP) excipients (refer to the current elritercept IB for a list of excipients) or recombinant proteins.

  • Prior use of elritercept, luspatercept, or sotatercept.

  • Prior use of hypomethylating agents (HMAs), isocitrate dehydrogenase inhibitor, lenalidomide, imetelstat, or immunosuppressive therapy given for treatment of MDS.

  • Iron chelation therapy initiated within 8 weeks before randomization. Participants on stable or decreasing doses of iron chelation therapy for ≥ 8 weeks are allowed.

  • Vitamin B12 or folate therapy initiated within 4 weeks before randomization. Participants on stable replacement doses for ≥ 4 weeks and without ongoing concurrent vitamin B12 or folate deficiency are allowed.

  • Androgen use within 8 weeks before randomization. Participants on stable androgen dosing for hypogonadism for ≥ 8 weeks are allowed.

  • High-dose systemic corticosteroid use within 4 weeks before randomization. Participants on stable chronic steroid doses of prednisone lesser than or equal to (≤) 10 milligrams per day (mg/day) or corticosteroid equivalent for ≥ 4 weeks are allowed.10 mg/day or corticosteroid equivalent for ≥ 4 weeks are allowed.

  • Treatment with any investigational drug within 28 days before Screening or, if the half-life of the product is known, within 5 times the half-life before Screening, whichever is longer.

  • Ongoing participation in another interventional clinical study.

  • Serum EPO level >500 U/L.

  • Platelet count ≥800 × 10^9 per liter (/L) or ≤25 × 10^9/L.

  • Absolute neutrophil count ≤ 500 per microliter (/µL).

  • Serum aspartate aminotransferase or alanine aminotransferase ≥3 × the upper limit of normal (ULN).

  • Total bilirubin ≥2 × ULN unless attributable to Gilbert's syndrome. Participants with known history of Gilbert syndrome with unconjugated bilirubin < 3 × ULN are allowed. Higher levels, if attributed to active RBC precursor destruction within the bone marrow (ineffective erythropoiesis), may be allowed upon medical monitor review.

  • Ferritin ≤ 50 micrograms per litre (μg/L).

  • Folate ≤2.0 nanograms per milliliter (ng/mL).

  • Vitamin B12 ≤200 picograms per milliliter (pg/mL).

  • Estimated glomerular filtration rate <30 milliliters per minute per 1.73 meter square (mL/min/1.73m^2) as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Collaboration equation.

  • Pregnant or lactating female.

  • Any other condition not specifically noted above that, in the opinion of the Investigator, would preclude the participant from participating in the study or could confound interpretation of data from the study.

  • Investigational site staff members directly involved in the conduct of the study and site staff members otherwise supervised by the Investigator, employees of the Sponsor or CRO directly involved in the conduct of the study, or immediate family members (defined as a spouse, parent, child, or sibling, whether biological or legally adopted).

  • For Participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults (per applicable French law [Art. L. 1121-6, Art. L. 1121-8, Art. L. 1121-8-1]).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Elritercept

Participants will be administered elritercept (TAK-226, KER-050), subcutaneously every 4 weeks, up to 48 weeks or until the end of treatment period.

Elritercept (TAK-226, KER-050) administered subcutaneously every 4 weeks.

Otros nombres:
  • KER-050
  • TAK-226
Comparador de placebos: Placebo

Participants will be administered elritercept (TAK-226, KER-050) matching-placebo, subcutaneously every 4 weeks, up to 48 weeks or until the end of treatment period.

Elritercept (TAK-226, KER-050) matching-placebo administered subcutaneously every 4 weeks.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Achieving Transfusion Independence (TI) for ≥8 Weeks
Periodo de tiempo: Baseline through Week 24

Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.

Baseline through Week 24

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Achieving TI for ≥24 Weeks
Periodo de tiempo: Baseline through Week 48

Transfusion independence is defined as the absence of any RBC transfusions in a period of at least 24 weeks after the first dose of the study treatment through week 48.

Baseline through Week 48
Percentage of Participants with High-transfusion Burden (HTB) Achieving TI for ≥8 weeks
Periodo de tiempo: Baseline through Week 24

Transfusion independence is defined as the absence of any RBC transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.

Baseline through Week 24
Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: From the time of signing the informed consent form through 60 days after the last dose of study treatment, approximately 6 years

An adverse event (AE) is defined as any untoward medical occurrence, in a clinical study participant administered a medicinal product, that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not it is related to study treatment. A TEAE is defined as an AE that commences on or after the first dose of the study treatment and within 60 days after the last dose of the study treatment, or analysis cutoff date, whichever is earlier. An SAE is any untoward medical occurrence that, at any dose: results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

From the time of signing the informed consent form through 60 days after the last dose of study treatment, approximately 6 years
Change from Baseline in Clinical Laboratory Values, Vital Signs, and Electrocardiograms (ECGs)
Periodo de tiempo: From the time of signing the informed consent form through safety follow-up, approximately 16 months

Change from baseline in clinical laboratory values, vital signs, and ECGs will be assessed.

From the time of signing the informed consent form through safety follow-up, approximately 16 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Study Director, Takeda

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de mayo de 2025

Finalización primaria (Estimado)

15 de septiembre de 2028

Finalización del estudio (Estimado)

5 de marzo de 2032

Fechas de registro del estudio

Enviado por primera vez

5 de julio de 2024

Primero enviado que cumplió con los criterios de control de calidad

11 de julio de 2024

Publicado por primera vez (Actual)

12 de julio de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • KER-050-D301
  • 2024-516009-22-00 (Ctis)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Criterios de acceso compartido de IPD

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .